stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) P/S ratio
As of 6 November 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a P/S ratio of 5.3×. Over the past ten years it has ranged from 1.0× (April 2025) to 35.3× (December 2020); the current reading is higher than 81% of that period. That is below the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.5× | (12.89%) |
| FY2024 | 2.9× | (5.76%) |
| FY2023 | 3.1× | 50.88% |
| FY2022 | 2.0× | (66.11%) |
| FY2021 | 6.0× | 50.70% |
| FY2020 | 4.0× | (88.32%) |
| FY2019 | 34.2× | 0.00% |
| FY2018 | 34.2× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 5.4× | 21.19% |
| Jun 2026 | 4.4× | 118.54% |
| Mar 2026 | 2.0× | (19.87%) |
| Dec 2025 | 2.5× | 17.06% |
| 24 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 2.0× |
| MRVI Maravai LifeSciences Holdings, Inc. | 5.3× |
| VIR Vir Biotechnology, Inc. compare | 6.8× |
| MESO Mesoblast Limited compare | 148× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)